title: New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect.
abstract: We predict, for the first time, that by using United States Food and Drug Administration approved concentrations of cisplatin, major radiosensitization may be achieved via photoelectric mechanism during concomitant chemoradiotherapy (CCRT). Our analytical calculations estimate that radiotherapy (RT) dose to cancer cells may be enhanced via this mechanism by over 100% during CCRT. The results proffer new potential for significantly enhancing CCRT via an emerging clinical scenario, where the cisplatin is released in-situ from RT biomaterials loaded with cisplatin nanoparticles.
authors.affiliation: Department of Physics and Applied Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA. Electronic address: Yucel_Altundal@student.um.edu.
authors.forename: Yucel
authors.initials: Y
authors.lastname: Altundal
authors.affiliation: Department of Physics and Applied Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA.
authors.forename: Gizem
authors.initials: G
authors.lastname: Cifter
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; University of Lyon Claude Bernard, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Detappe
authors.affiliation: Department of Physics and Applied Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA.
authors.forename: Erno
authors.initials: E
authors.lastname: Sajo
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Tsiamas
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Piotr
authors.initials: P
authors.lastname: Zygmanski
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Ross
authors.initials: R
authors.lastname: Berbeco
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Cormack
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Mike
authors.initials: M
authors.lastname: Makrigiorgos
authors.affiliation: Department of Physics and Applied Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Wilfred
authors.initials: W
authors.lastname: Ngwa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001918:Brachytherapy; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D004583:Electrons; D006801:Humans; D008027:Light; D009369:Neoplasms / Q000628:therapy; D011879:Radiotherapy Dosage; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: Brachytherapy; Chemoradiotherapy; Cisplatin nanoparticles; Dose enhancement; Radiotherapy